TAR-200 Yields Complete Responses in BCG-Unresponsive High-Risk NMIBC
Efficacy and safety data from the phase 2b SUNRISE-1 trial support the ongoing evaluations of TAR-200 as a treatment for patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer.
Amivantamab ± Lazertinib Improves PFS Vs Chemo in EGFR+ Advanced NSCLC
Amivantamab plus chemotherapy may be the new standard of care for patients with EGFR-mutated advanced non–small cell lung cancer that has progressed following osimertinib, according to Antonio Passaro, MD, PhD.
PFS Improves With Dato-DXd Vs Docetaxel in Advanced NSCLC Subgroups
Objective response rate appears to be higher with datopotamab deruxtecan compared with docetaxel among patients with advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 study.
Sobuzoxane Combo Extends Survival in Elderly DLBCL Group
Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden.
Bortezomib Regimen Yields Responses in B-Cell Marginal Zone Lymphoma
A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.
Amivantamab Combo Improves Outcomes Vs Osimertinib in EGFR-Mutated NSCLC
Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.
Lenvatinib Combo Demonstrates Safety, Activity in Metastatic ESCC
Investigators will continue to assess the efficacy and safety of lenvatinib plus pembrolizumab and chemotherapy as frontline treatment for patients with metastatic esophageal squamous cell carcinoma in part 2 of the LEAP-014 study.
Pembrolizumab Combo Yields Enduring Benefits in Advanced Endometrial Cancer
Data from the phase 3 KEYNOTE-775 trial support lenvatinib plus pembrolizumab as a standard therapy option for patients with previously treated advanced endometrial cancer.
EX103 Yields Preliminary Activity, Tolerability in R/R Non-Hodgkin Lymphoma
Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.
Data Show rPFS Benefit with 177Lu-PSMA-617 in Metastatic CRPC
Median radiographic progression-free survival appears to be higher in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 than those receiving androgen receptor pathway inhibitors.
PFS Improves With Dato-DXd Vs Chemo in HR+/HER2– Metastatic Breast Cancer
Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for those with hormone receptor–positive breast cancer.
mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma
Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.
Lenvatinib Combo Improves Responses Vs Sunitinib in Clear Cell RCC
Pembrolizumab plus lenvatinib yields clinically relevant efficacy in clear cell renal cell carcinoma subgroups based on site of metastasis and number of metastatic sites in the phase 3 CLEAR trial.
Dostarlimab Yields Benefits in Endometrial Carcinoma Molecular Subgroups
Data from the phase 3 RUBY trial may support the use of dostarlimab plus chemotherapy as a new standard of care in patients with newly diagnosed primary advanced or recurrent endometrial carcinoma.
T-DXd Elicits Encouraging Clinical Benefits in HER2-Mutated Solid Tumors
Trastuzumab deruxtecan produces enduring responses among patients with HER2-mutated solid tumors in the phase 2 DESTINY-PanTumor01 trial.
Enfortumab Vedotin Combo Boosts Survival Vs Chemo in Urothelial Carcinoma
Data from the phase 3 EV-302 trial support enfortumab vedotin plus pembrolizumab as a potential standard of care in locally advanced or metastatic urothelial carcinoma.
Cabozantinib Improves PFS Vs Placebo in Advanced Neuroenocrine Tumors
Cabozantinib may become a new treatment option for those with previously treated advanced neuroendocrine tumors based on data from the phase 3 CABINET trial.
Chemotherapy/Chemoradiation Improves PFS/OS in Advanced Cervical Cancer
Data from the INTERLACE trial support induction chemotherapy prior to chemoradiation as a potential standard in locally advanced cervical cancer.
Data Highlight Survival Benefits with Tisotumab Vedotin in Cervical Cancer
Findings from the phase 3 innovaTV trial support tisotumab vedotin as a potential standard of care for patients with metastatic or recurrent cervical cancer following disease progression.
Nivolumab/Chemo Yields Survival Benefits in Metastatic Urothelial Carcinoma
Treatment with nivolumab plus gemcitabine-cisplatin appears to confer rapid and enduring responses in patients with unresectable or metastatic urothelial carcinoma in the phase 3 CheckMate 901 trial.
MAGNITUDE Trial Highlights OS Benefit with Niraparib Combo in BRCA+ mCRPC
Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.
Survival Outcomes Do Not Improve With Pembrolizumab/Enzalutamide in mCRPC
Subgroup analyses in the phase 3 KEYNOTE-641 trial do not indicate an overall survival improvement with pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer.
Meaningful Activity Experienced With Lifileucel in Melanoma Subtype
Those with advanced mucosal melanoma who were treated with lifileucel saw clinically meaningful activity.
Improvement in Efficacy End Points Observed With Belzutifan in Clear Cell RCC
Belzutifan vs everolimus saw increased progression-free survival and objective response rate in patients with pretreated advanced clear cell renal cell carcinoma.
Etigilimab Plus Nivolumab Demonstrates Tolerability in Advanced Solid Tumors
Results from the phase 1b/2 ACTIVATE trial showed tolerability among the combination of etigilimab plus nivolumab in patients with recurrent or advanced solid tumors.
Statistically Significant Improvement in PFS, ORR With Selpercatinib in Advanced Thyroid Cancer
Selpercatinib significantly improved efficacy in patients with advanced, multikinase inhibitor–naïve, RET-mutant medullary thyroid cancer.
Amivantimab Combo Yields Increased PFS in EGFR Exon 20 NSCLC
Amivantimab produces superior progression-free survival in EGFR exon 20 insertion–positive non–small-cell lung cancer.
First-Line Selpercatinib Shows PFS Benefit in RET+ NSCLC
Patients with RET fusion–positive non–small cell lung cancer experienced improved progression-free survival with first-line selpercatinib.
DFS Improvement Observed With Alectinib in ALK+ NSCLC Population
Alectinib improves disease-free survival in patients with ALK-positive non–small-cell lung cancer.
Osimertinib Combo Lessens CNS Progression in EGFR NSCLC
Central nervous system progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.
2 Clarke Drive Cranbury, NJ 08512